$MNPR
Monopar Therapeutics Stock $mnpr

$mnpr Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000165495422014939 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$808.7K	$675.1K	$631.7K
YoY Change	15.79%	6.87%	61.97%
% of Gross Profit
Research & Development	$2.103M	$1.732M	$1.827M
YoY Change	6.07%	-5.2%	45.5%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.909M	$2.407M	$2.459M
YoY Change	8.5%	-2.1%	49.21%
Operating Profit		-$2.407M	-$2.459M
YoY Change		-2.1%	49.21%
Interest Expense	$12.66K	$7.700K	$580.00
YoY Change	2288.68%	1227.59%	-94.2%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.896M	-$2.400M	-$2.458M
YoY Change	8.05%	-2.39%	49.9%
Income Tax
% Of Pretax Income
Net Earnings	-$2.896M	-$2.400M	-$2.458M
YoY Change	8.05%	-2.39%	49.96%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.19
Diluted Earnings Per Share	-$0.22	-$188.1K	-$195.4K
COMMON SHARES
Basic Shares Outstanding	12.86M shares	12.73M shares	12.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.12M	$14.32M	$22.34M
YoY Change	-35.38%	-35.92%	24.26%
Cash & Equivalents	$8.186M	$14.32M	$22.34M
Short-Term Investments	$4.934M
Other Short-Term Assets	$45.98K	$55.70K	$106.8K
YoY Change	-78.88%	-47.85%	6.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$13.17M	$14.37M	$22.45M
YoY Change	-35.84%	-35.98%	24.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$61.23K	$72.89K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$68.86K
YoY Change			-1.63%
Total Long-Term Assets	$61.23K	$72.89K	$68.86K
YoY Change		5.85%	-1.63%
TOTAL ASSETS
Total Short-Term Assets	$13.17M	$14.37M	$22.45M
Total Long-Term Assets	$61.23K	$72.89K	$68.86K
Total Assets	$13.23M	$14.45M	$22.52M
YoY Change	-35.55%	-35.85%	23.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.080M	$1.867M	$1.240M
YoY Change	94.89%	50.53%	129.62%
Accrued Expenses	$48.58K	$47.80K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.129M	$1.914M	$1.240M
YoY Change	97.96%	54.39%	103.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$8.410K	$20.85K
YoY Change
Total Long-Term Liabilities	$8.410K	$20.85K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.129M	$1.914M	$1.240M
Total Long-Term Liabilities	$8.410K	$20.85K	$0.00
Total Liabilities	$3.137M	$1.935M	$1.240M
YoY Change	98.5%	56.07%	87.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$51.80M	-$48.91M	-$38.61M
YoY Change	25.47%	26.68%
Common Stock	$12.95K	$12.86K	$12.59K
YoY Change	2.77%	2.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.09M	$12.51M	$21.28M
YoY Change
Total Liabilities & Shareholders Equity	$13.23M	$14.45M	$22.52M
YoY Change	-35.55%	-35.85%	23.99%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$2.896M	-$2.400M	-$2.458M
YoY Change	8.05%	-2.39%	49.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.302M	-$2.148M	-$1.941M
YoY Change	-35.93%	10.67%	49.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$4.919M
YoY Change
Cash From Investing Activities	-$4.919M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	138.7K	-23.73K	-9.980K
YoY Change	-1885.46%	137.78%	-100.15%
NET CHANGE
Cash From Operating Activities	-1.302M	-2.148M	-1.941M
Cash From Investing Activities	-4.919M
Cash From Financing Activities	138.7K	-23.73K	-9.980K
Net Change In Cash	-6.082M	-2.172M	-1.951M
YoY Change	198.17%	11.32%	-135.87%
FREE CASH FLOW
Cash From Operating Activities	-$1.302M	-$2.148M	-$1.941M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-24003	usd
CY2021Q2	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	357593	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	23353632	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1935152	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1580543	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12855735	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12598125	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001645469
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12598125	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12855735	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39070
	dei	Entity Registrant Name EntityRegistrantName	MONOPAR THERAPEUTICS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0463781
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1000 Skokie Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
	dei	Entity Address City Or Town EntityAddressCityOrTown	Wilmette
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60091
	dei	City Area Code CityAreaCode	847
	dei	Local Phone Number LocalPhoneNumber	388-0349
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	MNPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12855735	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14316461	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20303869	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	55700	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	217745	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	14372161	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	20521614	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	72889	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q3	us-gaap	Assets Assets	14445050	usd
CY2021Q4	us-gaap	Assets Assets	20521614	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1914302	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1580543	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1914302	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1580543	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20850	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001645469
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	12856	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	12598	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61361740	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60220016	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	42985	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3160	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48907683	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41288383	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12509898	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18941071	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14445050	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20521614	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1732230	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1827322	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5488633	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4510531	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	675115	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	631698	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2139246	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1935599	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2407345	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2459020	usd
	us-gaap	Operating Expenses OperatingExpenses	7627879	usd
	us-gaap	Operating Expenses OperatingExpenses	6446130	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2407345	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2459020	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	577	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	8579	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	23499	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2399647	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2458443	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7619300	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6422631	usd
CY2022Q3	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	25519	usd
CY2021Q3	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	9	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	46145	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	2726	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2374128	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2458434	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7573155	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6419905	usd
CY2022Q3	mnpr	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.19
CY2021Q3	mnpr	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.20
	mnpr	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.60
	mnpr	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.52
CY2022Q3	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	12754685	shares
CY2021Q3	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	12582728	shares
	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	12664387	shares
	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	12432318	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18941071	usd
CY2022Q1	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2022Q1	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-16666	usd
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12598125	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12855735	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39070
	dei	Entity Registrant Name EntityRegistrantName	MONOPAR THERAPEUTICS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0463781
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1000 Skokie Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
	dei	Entity Address City Or Town EntityAddressCityOrTown	Wilmette
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60091
	dei	City Area Code CityAreaCode	847
	dei	Local Phone Number LocalPhoneNumber	388-0349
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	MNPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12855735	shares
	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	12432318	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18941071	usd
CY2022Q1	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2022Q1	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-16666	usd
CY2022Q1	mnpr	Stock Based Compensation Non Cash StockBasedCompensationNonCash	499812	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-2456722	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-584	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16966911	usd
CY2022Q2	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-29655	usd
CY2022Q2	mnpr	Issuance Of Common Stock Upon Exercise Of Stock Options Amount IssuanceOfCommonStockUponExerciseOfStockOptionsAmount	41	usd
CY2022Q2	mnpr	Stock Based Compensation Non Cash StockBasedCompensationNonCash	357293	usd
CY2022Q2	mnpr	Offering Costs OfferingCosts	-35846	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2762931	usd
CY2022Q2	mnpr	Other Comprehensive Income OtherComprehensiveIncome	21210	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14517023	usd
CY2022Q3	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2022Q3	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-10672	usd
CY2022Q3	mnpr	Issuance Of Common Stock Upon Exercise Of Stock Options Amount IssuanceOfCommonStockUponExerciseOfStockOptionsAmount	128	usd
CY2022Q3	mnpr	Stock Based Compensation Non Cash StockBasedCompensationNonCash	390741	usd
CY2022Q3	mnpr	Offering Costs OfferingCosts	-13194	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-2399647	usd
CY2022Q3	mnpr	Other Comprehensive Income OtherComprehensiveIncome	25519	usd
CY2022Q1	mnpr	Stock Based Compensation Non Cash StockBasedCompensationNonCash	499812	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-2456722	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-584	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16966911	usd
CY2022Q2	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2022Q2	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-29655	usd
CY2022Q2	mnpr	Issuance Of Common Stock Upon Exercise Of Stock Options Amount IssuanceOfCommonStockUponExerciseOfStockOptionsAmount	41	usd
CY2022Q2	mnpr	Stock Based Compensation Non Cash StockBasedCompensationNonCash	357293	usd
CY2022Q2	mnpr	Offering Costs OfferingCosts	-35846	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2762931	usd
CY2022Q2	mnpr	Other Comprehensive Income OtherComprehensiveIncome	21210	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14517023	usd
CY2022Q3	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2022Q3	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-10672	usd
CY2022Q3	mnpr	Issuance Of Common Stock Upon Exercise Of Stock Options Amount IssuanceOfCommonStockUponExerciseOfStockOptionsAmount	128	usd
CY2022Q3	mnpr	Stock Based Compensation Non Cash StockBasedCompensationNonCash	390741	usd
CY2022Q3	mnpr	Offering Costs OfferingCosts	-13194	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-2399647	usd
CY2022Q3	mnpr	Other Comprehensive Income OtherComprehensiveIncome	25519	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12509898	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	15691991	usd
CY2021Q1	mnpr	Issuance Of Common Stock Under A Capital On Demandtm Sales Agreement With Jonestrading Institutional Services Llc Net Of Commissions And Fees Three Three Eight One Five Three Amount IssuanceOfCommonStockUnderACapitalOnDemandtmSalesAgreementWithJonestradingInstitutionalServicesLlcNetOfCommissionsAndFeesThreeThreeEightOneFiveThreeAmount	10925312	usd
CY2021Q1	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-21500	usd
CY2021Q1	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2021Q1	mnpr	Issuance Of Common Stock Upon Exercise Of Stock Options Amount IssuanceOfCommonStockUponExerciseOfStockOptionsAmount	17478	usd
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	368232	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-1884019	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2774	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	25100268	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2080169	usd
CY2021Q3	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-9978	usd
CY2021Q3	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	392065	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-2458443	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	21277285	usd
	us-gaap	Profit Loss ProfitLoss	-7619300	usd
	us-gaap	Profit Loss ProfitLoss	-6422631	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1247846	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1117890	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	162017	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-44111	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	282435	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	63356	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	249	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5926753	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5285496	usd
	mnpr	Payment Of Sale Of Common Stock And Other Investments PaymentOfSaleOfCommonStockAndOtherInvestments	0	usd
	mnpr	Payment Of Sale Of Common Stock And Other Investments PaymentOfSaleOfCommonStockAndOtherInvestments	10925312	usd
	mnpr	Payment Of Financing And Stock Issuance Costs Other PaymentOfFinancingAndStockIssuanceCostsOther	-49040	usd
	mnpr	Payment Of Financing And Stock Issuance Costs Other PaymentOfFinancingAndStockIssuanceCostsOther	0	usd
	mnpr	Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits	-56993	usd
	mnpr	Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits	-55481	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2080169	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	15691991	usd
CY2021Q1	mnpr	Issuance Of Common Stock Under A Capital On Demandtm Sales Agreement With Jonestrading Institutional Services Llc Net Of Commissions And Fees Three Three Eight One Five Three Amount IssuanceOfCommonStockUnderACapitalOnDemandtmSalesAgreementWithJonestradingInstitutionalServicesLlcNetOfCommissionsAndFeesThreeThreeEightOneFiveThreeAmount	10925312	usd
CY2021Q1	mnpr	Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount	-21500	usd
CY2021Q1	mnpr	Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2021Q1	mnpr	Issuance Of Common Stock Upon Exercise Of Stock Options Amount IssuanceOfCommonStockUponExerciseOfStockOptionsAmount	17478	usd
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	368232	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-1884019	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2774	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	392065	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-2458443	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	21277285	usd
	us-gaap	Profit Loss ProfitLoss	-7619300	usd
	us-gaap	Profit Loss ProfitLoss	-6422631	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1247846	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1117890	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	162017	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-44111	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	63356	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	249	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5926753	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5285496	usd
	mnpr	Payment Of Sale Of Common Stock And Other Investments PaymentOfSaleOfCommonStockAndOtherInvestments	0	usd
	mnpr	Payment Of Sale Of Common Stock And Other Investments PaymentOfSaleOfCommonStockAndOtherInvestments	10925312	usd
	mnpr	Payment Of Financing And Stock Issuance Costs Other PaymentOfFinancingAndStockIssuanceCostsOther	-49040	usd
	mnpr	Payment Of Financing And Stock Issuance Costs Other PaymentOfFinancingAndStockIssuanceCostsOther	0	usd
	mnpr	Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits	-56993	usd
	mnpr	Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits	-55481	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	169	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17478	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-105864	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10887309	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	45209	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5987408	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5604455	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20303869	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16737109	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14316461	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22341564	usd
	mnpr	Lease Liability Arising Out Of Obtaining Right Of Use Asset LeaseLiabilityArisingOutOfObtainingRightOfUseAsset	92359	usd
	mnpr	Lease Liability Arising Out Of Obtaining Right Of Use Asset LeaseLiabilityArisingOutOfObtainingRightOfUseAsset	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 1 – Nature of Business and Liquidity</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Nature of Business</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Monopar Therapeutics Inc. (“Monopar” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve quality of life for cancer patients. Monopar currently has four compounds in development: 1) Validive® (clonidine hydrochloride mucobuccal tablet; clonidine HCI MBT), a Phase 2b/3 clinical stage, first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (“SOM”) in oropharyngeal cancer patients; 2) camsirubicin (generic name for MNPR-201, GPX-150; 5-imino-13-deoxydoxorubicin), a Phase 1b clinical stage novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; 3) MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for advanced cancers and severe COVID-19; and 4) an early stage camsirubicin analog, MNPR-202, for various cancers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Liquidity</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred an accumulated deficit of approximately $48.9 million as of September 30, 2022. To date, the Company has primarily funded its operations with the net proceeds from the Company’s initial public offering of its common stock on Nasdaq, sales of its common stock in the public market through an at-the-market sales agreement, private placements of convertible preferred stock and of common stock and cash provided in the camsirubicin asset purchase transaction. Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through November 2023. The Company’s ability to fund its future operations, including the continued clinical development of Validive and camsirubicin, is dependent upon its ability to execute its business strategy, to obtain additional funding and/or to execute collaborative research agreements. There can be no certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The coronavirus disease (“COVID-19”) pandemic continues to affect economies and business around the world. In response to COVID-19 and its effects on clinical trials, in 2020 Monopar modified the original adaptive design Phase 3 clinical trial for its lead product candidate, Validive, to be a Phase 2b/3 clinical trial (“VOICE”) to better fit the types of trials which can enroll sufficient required patients in the current environment. This modification allowed the Company to activate the VOICE clinical trial without requiring near-term financing. To complete the VOICE clinical program, including, if required, completing a second Phase 3 confirmatory clinical trial, Monopar will require additional funding in the millions or tens of millions of dollars (depending on if the Company has consummated a collaboration or partnership or neither for Validive), which it is planning to pursue within the next 12 months. Due to many uncertainties, the Company is unable to estimate the pandemic’s financial impact or duration in light of global vaccine rollouts, treatment options and potential surges of new cases from current or future COVID-19 variants, or its potential impact on the Company’s current clinical trials, including COVID-19’s effect on drug candidate manufacturing, shipping, patient recruitment at clinical sites and regulatory agencies around the globe.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Russia-Ukraine war and resulting sanctions against Russia and Russian entities or allies have increased fuel costs and may cause shipping delays and the broader economic, trade and financial market consequences are uncertain at this time, which may increase the cost of supplies for the Company’s clinical materials, may delay the manufacture of its clinical materials, may increase costs of other goods and services or make it more difficult or costly to raise additional financing, any of which could cause an adverse effect on the Company’s clinical programs and on the Company’s financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Market variables, such as inflation of product costs, labor rates and fuel, freight and energy costs, as well as geopolitical events could likely cause the Company to suffer significant increases in its operating and administrative expenses.</p>
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	169	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17478	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-105864	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10887309	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	45209	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	2642	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5987408	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5604455	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20303869	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16737109	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14316461	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22341564	usd
	mnpr	Lease Liability Arising Out Of Obtaining Right Of Use Asset LeaseLiabilityArisingOutOfObtainingRightOfUseAsset	92359	usd
	mnpr	Lease Liability Arising Out Of Obtaining Right Of Use Asset LeaseLiabilityArisingOutOfObtainingRightOfUseAsset	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 1 – Nature of Business and Liquidity</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Nature of Business</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Monopar Therapeutics Inc. (“Monopar” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve quality of life for cancer patients. Monopar currently has four compounds in development: 1) Validive® (clonidine hydrochloride mucobuccal tablet; clonidine HCI MBT), a Phase 2b/3 clinical stage, first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (“SOM”) in oropharyngeal cancer patients; 2) camsirubicin (generic name for MNPR-201, GPX-150; 5-imino-13-deoxydoxorubicin), a Phase 1b clinical stage novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; 3) MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for advanced cancers and severe COVID-19; and 4) an early stage camsirubicin analog, MNPR-202, for various cancers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Liquidity</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred an accumulated deficit of approximately $48.9 million as of September 30, 2022. To date, the Company has primarily funded its operations with the net proceeds from the Company’s initial public offering of its common stock on Nasdaq, sales of its common stock in the public market through an at-the-market sales agreement, private placements of convertible preferred stock and of common stock and cash provided in the camsirubicin asset purchase transaction. Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through November 2023. The Company’s ability to fund its future operations, including the continued clinical development of Validive and camsirubicin, is dependent upon its ability to execute its business strategy, to obtain additional funding and/or to execute collaborative research agreements. There can be no certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The coronavirus disease (“COVID-19”) pandemic continues to affect economies and business around the world. In response to COVID-19 and its effects on clinical trials, in 2020 Monopar modified the original adaptive design Phase 3 clinical trial for its lead product candidate, Validive, to be a Phase 2b/3 clinical trial (“VOICE”) to better fit the types of trials which can enroll sufficient required patients in the current environment. This modification allowed the Company to activate the VOICE clinical trial without requiring near-term financing. To complete the VOICE clinical program, including, if required, completing a second Phase 3 confirmatory clinical trial, Monopar will require additional funding in the millions or tens of millions of dollars (depending on if the Company has consummated a collaboration or partnership or neither for Validive), which it is planning to pursue within the next 12 months. Due to many uncertainties, the Company is unable to estimate the pandemic’s financial impact or duration in light of global vaccine rollouts, treatment options and potential surges of new cases from current or future COVID-19 variants, or its potential impact on the Company’s current clinical trials, including COVID-19’s effect on drug candidate manufacturing, shipping, patient recruitment at clinical sites and regulatory agencies around the globe.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Russia-Ukraine war and resulting sanctions against Russia and Russian entities or allies have increased fuel costs and may cause shipping delays and the broader economic, trade and financial market consequences are uncertain at this time, which may increase the cost of supplies for the Company’s clinical materials, may delay the manufacture of its clinical materials, may increase costs of other goods and services or make it more difficult or costly to raise additional financing, any of which could cause an adverse effect on the Company’s clinical programs and on the Company’s financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Market variables, such as inflation of product costs, labor rates and fuel, freight and energy costs, as well as geopolitical events could likely cause the Company to suffer significant increases in its operating and administrative expenses.</p>
CY2022Q3	mnpr	Accumulated Deficit AccumulatedDeficit	-48900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</p>
	mnpr	Maturity Date MaturityDate	P90Y
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</p>
	mnpr	Maturity Date MaturityDate	P90Y
CY2022Q3	mnpr	Insurance Premiums Dues Subscription And Software Cost Paid In Advance InsurancePremiumsDuesSubscriptionAndSoftwareCostPaidInAdvance	10000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents at two reputable financial institutions. As of September 30, 2022, the balance at one financial institution was in excess of the $ 250,000 Federal Deposit Insurance Corporation (“FDIC”) insurable limit. The Company has not experienced any losses on its deposits since inception and management believes the Company is not exposed to significant risks with respect to these financial institutions.</p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	13924216	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	13924216	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20014205	usd
CY2022Q3	mnpr	Insurance Premiums Dues Subscription And Software Cost Paid In Advance InsurancePremiumsDuesSubscriptionAndSoftwareCostPaidInAdvance	10000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents at two reputable financial institutions. As of September 30, 2022, the balance at one financial institution was in excess of the $ 250,000 Federal Deposit Insurance Corporation (“FDIC”) insurable limit. The Company has not experienced any losses on its deposits since inception and management believes the Company is not exposed to significant risks with respect to these financial institutions.</p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20014205	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20014205	usd
CY2021Q3	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	12582728	shares
	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	12664387	shares
	mnpr	Potentially Dilutive Securities PotentiallyDilutiveSecurities	1928152	shares
	mnpr	Potentially Dilutive Securities PotentiallyDilutiveSecurities	1761007	shares
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20014205	usd
CY2022Q3	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	12754685	shares
CY2021Q3	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	12582728	shares
	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	12664387	shares
	mnpr	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	12432318	shares
	mnpr	Potentially Dilutive Securities PotentiallyDilutiveSecurities	1928152	shares
	mnpr	Potentially Dilutive Securities PotentiallyDilutiveSecurities	1761007	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	mnpr	Common Stock Aggregate Offering Price Description CommonStockAggregateOfferingPriceDescription	4870000	usd
CY2022Q3	mnpr	Common Stock Issued And Oustanding CommonStockIssuedAndOustanding	12855735	shares
	mnpr	Description Of Exercise Price DescriptionOfExercisePrice	exercise prices ranging from $1.83 to $2.35 per share which vest over 4 years
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1258577	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.47
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	403476	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.27
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	115151	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.49
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2913	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1543989	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	582064	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	337103	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.13
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1620950	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	510286	shares
	mnpr	Weighted Average Exercise Price Unvested Options Outstanding Expected To Vest WeightedAverageExercisePriceUnvestedOptionsOutstandingExpectedToVest	4.03
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	1620950	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	mnpr	Common Stock Aggregate Offering Price Description CommonStockAggregateOfferingPriceDescription	4870000	usd
CY2022Q3	mnpr	Common Stock Issued And Oustanding CommonStockIssuedAndOustanding	12855735	shares
	mnpr	Description Of Exercise Price DescriptionOfExercisePrice	exercise prices ranging from $1.83 to $2.35 per share which vest over 4 years
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1258577	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.47
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	403476	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.27
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	115151	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.49
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2913	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1543989	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	582064	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	337103	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.13
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	168000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.001
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1620950	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	510286	shares
	mnpr	Weighted Average Exercise Price Unvested Options Outstanding Expected To Vest WeightedAverageExercisePriceUnvestedOptionsOutstandingExpectedToVest	4.03
CY2022Q3	mnpr	Operatingleaserightofuseassetnoncurrent Operatingleaserightofuseassetnoncurrent	72889	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47801	usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20850	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	68651	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	1620950	shares
	mnpr	Number Of Shares Subjected To Fully Vested And Exercisable NumberOfSharesSubjectedToFullyVestedAndExercisable	1110664	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	99000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	582064	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400476	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.60
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.48
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	205397	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	280883	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	757976	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	838901	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	600000	usd
CY2022Q3	mnpr	Weighted Average Exercise Price WeightedAverageExercisePrice	4.29
CY2022Q3	mnpr	Weighted Average Vested Exercise Price WeightedAverageVestedExercisePrice	4.41
CY2022Q3	mnpr	Weighted Average Stock Options Expected To Vest WeightedAverageStockOptionsExpectedToVest	4.03
CY2022Q3	mnpr	Unamortized Unvested Balance Of Stock Base Compensation UnamortizedUnvestedBalanceOfStockBaseCompensation	2500000	usd
	mnpr	Unamortized Unvested Balance Of Stock Base Compensation Period UnamortizedUnvestedBalanceOfStockBaseCompensationPeriod	P2Y7M6D
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	13466	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	37134	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	41499	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50856	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8476	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	72046	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3395	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	68651	usd
	mnpr	Schdule Of Weighted Average Remaining Lease Term And Discount Rate SchduleOfWeightedAverageRemainingLeaseTermAndDiscountRate	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"/><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Lease term: </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Operating leases </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.42 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Discount rate: </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Operating lease</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6.50%</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	mnpr	Operating Lease Weighted Average Remaining Lease Terms1 OperatingLeaseWeightedAverageRemainingLeaseTerms1	P1Y5M1D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	72889	usd
CY2021Q3	mnpr	Operatingleaserightofuseassetnoncurrent Operatingleaserightofuseassetnoncurrent	0	usd
	mnpr	Number Of Shares Subjected To Fully Vested And Exercisable NumberOfSharesSubjectedToFullyVestedAndExercisable	1110664	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	4000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	99000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400476	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.60
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.48
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	205397	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	280883	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	757976	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	838901	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	600000	usd
CY2022Q3	mnpr	Weighted Average Exercise Price WeightedAverageExercisePrice	4.29
CY2022Q3	mnpr	Weighted Average Vested Exercise Price WeightedAverageVestedExercisePrice	4.41
CY2022Q3	mnpr	Weighted Average Stock Options Expected To Vest WeightedAverageStockOptionsExpectedToVest	4.03
CY2022Q3	mnpr	Unamortized Unvested Balance Of Stock Base Compensation UnamortizedUnvestedBalanceOfStockBaseCompensation	2500000	usd
	mnpr	Unamortized Unvested Balance Of Stock Base Compensation Period UnamortizedUnvestedBalanceOfStockBaseCompensationPeriod	P2Y7M6D
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	14057	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	13466	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	37134	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	41499	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12714	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50856	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8476	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	72046	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3395	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	68651	usd
	mnpr	Operating Lease Weighted Average Remaining Lease Terms1 OperatingLeaseWeightedAverageRemainingLeaseTerms1	P1Y5M1D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	72889	usd
CY2021Q3	mnpr	Operatingleaserightofuseassetnoncurrent Operatingleaserightofuseassetnoncurrent	0	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47801	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20850	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	68651	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	usd

Files In Submission

Name	View Source	Status
0001654954-22-014939-index-headers.html	Edgar Link	pending
0001654954-22-014939-index.html	Edgar Link	pending
0001654954-22-014939.txt	Edgar Link	pending
0001654954-22-014939-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mnpr-20220930.xsd	Edgar Link	pending
mnpr_10q.htm	Edgar Link	pending
mnpr_10qimg79.jpg	Edgar Link	pending
mnpr_ex311.htm	Edgar Link	pending
mnpr_ex312.htm	Edgar Link	pending
mnpr_ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
mnpr-20220930_cal.xml	Edgar Link	unprocessable
mnpr-20220930_lab.xml	Edgar Link	unprocessable
mnpr-20220930_pre.xml	Edgar Link	unprocessable
mnpr-20220930_def.xml	Edgar Link	unprocessable
mnpr_10q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MNPR
Monopar Therapeutics Stock $mnpr

2022 Q4 Form 10-Q Financial Statement

#000165495422014939 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNPR Monopar Therapeutics Stock $mnpr

2022 Q4 Form 10-Q Financial Statement

#000165495422014939 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNPR
Monopar Therapeutics Stock $mnpr